This study initially characterizes a prospective cohort of patients with TBI admitted to the NICU in an academic center in the Andean region in Colombia. The group with an unfavorable outcome was older, had lower GCS on admission, higher AISh, higher probability of an unfavorable outcome by the IMPACT-TBI model, higher APACHE II, and higher Charlson score. Among vital signs and laboratory data, the only documented difference was a higher PaCO2 on admission for those with an unfavorable outcome. In terms of in-hospital procedures, the group with an unfavorable outcome required more ventilatory and hemodynamic support, underwent neurosurgical interventions and tracheostomy more often, and had a longer LOS in the NICU. After adjusting for age, severity of TBI, and APACHE II, PaCO2 remained directly correlated with an unfavorable outcome at 6 months. A higher PaCO2 was associated with an unfavorable 6-month outcome for all the study groups and the group on ventilatory support. In the subgroup, without ventilatory support, this correlation was not maintained. The mean PaCO2 in the subgroup without ventilatory support was lower than those on mechanical ventilation. The lower PaCO2 levels observed in the non-ventilated group may be associated with the inherently lower baseline levels of PaCO2 in populations residing at higher altitudes. Consequently, this suggests a potential difference in the way regulatory mechanisms are established (10, 13).
The demographic characteristics of the studied cohort are similar to what others have found in terms of age and cause of trauma (42, 43). TBI affects predominantly the adult male population in their fourth or fifth decade of life, and the leading causes of injury are road accidents and falls. This has been consistent in several prospective studies, including the European and Chinese cohorts of CENTER-TBI and the TRACK-TBI for the US (5, 42, 44). Regarding mortality and functional outcomes, the ICU stratum of the European Center-TBI found 43.1% and 21.3% rates of an unfavorable outcome (GOSE < 5) and mortality, respectively. The results in our study are similar in both mortality (24%) and unfavorable outcome (30%), bearing in mind that the definition we used for unfavorable outcome was GOSE < 4 (44). There is no standardized manner to dichotomize GOSE, and definitions vary across studies (45, 46). TBI patients might show functional and cognitive improvement even 1 year after the trauma (47, 48), depending on their recovery trajectory. GOSE equal to 4 refers to a person who requires partial supervision and assistance but can be on their own at home for at least 8 hours a day. Therefore, we considered it reasonable to define GOSE ≥ 4 as the favorable outcome, considering that those patients are already partially independent at home and still have the potential for further progress.
Several studies have pointed out that older and more severely injured TBI patients have more frequent severe disability and functional dependence after TBI (49, 50). Moderate and severe TBI cases are usually admitted to the NICU, where interventions are guided by targets that aim to protect the brain from a secondary injury (51). Henceforth, it is also the more severely traumatized patient who needs more assistance in terms of respiratory, hemodynamic, and metabolic support as well as surgical interventions (52, 53). In our cohort, the group with unfavorable outcomes was older and had a more severe TBI on admission. Therefore, it could be expected that it is, in turn, the group that received a higher burden of care, including mechanical ventilation, vasopressors, neurosurgical and tracheostomy procedures, and was more exposed to complications like in-hospital infections and longer ICU stays. This reflects the complexity of treatment and prognosis when many factors are involved, leaving aside the variability of management across centers and regions (53). Despite this challenge, some prognostic models have been developed and validated, for instance, The Corticosteroid Randomization After Significant Head Injury (CRASH) model and the International Mission for Prognosis and Analysis of Clinical Trials (IMPACT) in TBI model (54, 55, 56). These models estimate the probability of disability and mortality and consider factors such as age, Glasgow motor score, pupillary reactivity, and imaging findings on head CT scans. We did not intend to develop a model, but we did identify some factors on admission associated with outcomes, including age, severity of TBI, APACHE II, and need for hemodynamic and ventilatory support. However, when assessing vital signs and laboratory tests, higher levels of PaCO2 on admission were associated with the unfavorable outcome, even after controlling for the age and severity of the injury. The role of PaCO2 in this context relies on its effect on the cerebral vasculature or vasoreactivity (57, 58). The brain has high metabolic demand, requiring a constant supply of oxygen and glucose (59). This supply is ensured through a tightly regulated cerebral blood flow that matches each brain region’s temporal and spatial metabolic requirements (60). One of those mechanisms is the vasomotor response to carbon dioxide, where cerebral arterioles dilate or contract according to changes in PaCO2. This response has a sigmoidal shape and functions within the 20–60 mmHg of PaCO2. Every 1 mmHg increase in PaCO2 corresponds to roughly a 4% increase in cerebral blood flow (61, 62), which in turn increases the cerebral blood volume resulting in an intracranial pressure elevation and finally affecting the cerebral perfusion pressure. Several cohorts have demonstrated the effect of PaCO2 management on outcomes, including mortality (21). However, variability in management exists across centers (63). Guidelines recommend a normal range ventilation, PaCO2 35–45 mmHg, and avoidance of hyperventilation and severe (< 25 mmHg) or moderate (< 30 mmHg) hypocapnia (8, 9) given the risk of brain ischemia.
In our cohort, we found a higher PaCO2 for those cases with an unfavorable outcome, and the multivariate analysis revealed a direct relation between admission PaCO2 levels and the probability of death and disability. The association remained for the subgroup on mechanical ventilation but not for those patients without ventilatory support. This could be expected given that PaCO2 in a ventilated patient depends mostly on the ventilator settings and can be adjusted to a specific goal. However, we would like to point out that most of our patients had PaCO2 levels within the recommended range of 35–45 mmHg and even below for those with a favorable outcome, 32 ± 6 mmHg. In addition, non-ventilated patients had even lower PaCO2 levels. These results underscore the importance and impact of PaCO2 as a crucial target in the management of ventilated TBI patients and raise the question of whether, for populations at higher altitudes, different PaCO2 goals should be pursued. Further investigation would be needed to answer this question, which will benefit a substantial proportion of the global TBI population living at higher altitudes.
Limitations of our study include a single-center study that requires further validation to make the results more generalizable. In addition, we only recorded the admission PaCO2 values rather than serial values.